Top

Published in:

28-03-2022 | Acute Coronary Syndrome | Review

Coronary Artery Disease and Aspirin Intolerance: Background and Insights on Current Management

Authors: Ravi A. Thakker, Leonardo Salazar, Deaa Abu Jazar, Pooja Bhakta, Bryan Baker, Chandani Patel, Ayman Elbadawi, Mayank Agarwal, Aiham Albaeni, Mohammed Saleh, Jonathan Esclovan, Danielle El Haddad, Hashim Alwash, Ankur Kalra, Sachin S. Goel, Robert Jay Widmer, Khaled Chatila, Wissam Khalife, Afaq Motiwala, Jennifer McCracken, Hani Jneid, Syed Gilani

Published in: Cardiology and Therapy | Issue 2/2022

Abstract

Aspirin is one of the most widely used medications across the global healthcare system and is the foundation in treating ischemic heart disease, as well as secondary prevention for ischemic and valvular heart disease. Challenges arise in treating patients with cardiovascular disease who have concomitant aspirin intolerance. Through an extensive review of the literature, we provide a comprehensive background on the pharmacology of aspirin, the mechanisms behind aspirin intolerance, the importance of aspirin in cardiovascular disease, and the management of aspirin intolerance in both acute coronary syndrome and stable coronary artery disease. Our review includes a multidisciplinary approach from the internist, allergist/immunologist, and cardiologist when evaluating this important patient population.

Ittaman SV, VanWormer JJ, Rezkalla SH. The role of aspirin in the prevention of cardiovascular disease. Clin Med Res. 2014;12(3–4):147–54. https://doi.org/10.3121/cmr.2013.1197 (Epub 2014 Feb 26).CrossRefPubMedPubMedCentral

Jenkins C, Costello J, Hodge L. Systematic review of prevalence of aspirin induced asthma and its implications for clinical practice. BMJ. 2004;328(7437):434. https://doi.org/10.1136/bmj.328.7437.434.CrossRefPubMedPubMedCentral

Ramanuja S, Breall JA, Kalaria VG. Approach to “aspirin allergy” in cardiovascular patients. Circulation. 2004;110(1):e1-4. https://doi.org/10.1161/01.CIR.0000134306.28561.2A.CrossRefPubMed

Vane JR, Botting RM. The mechanism of action of aspirin. Thromb Res. 2003;110(5–6):255–8. https://doi.org/10.1016/s0049-3848(03)00379-7.CrossRefPubMed

Flower R. What are all the things that aspirin does? BMJ. 2003;327(7415):572–3. https://doi.org/10.1136/bmj.327.7415.572.CrossRefPubMedPubMedCentral

Needs CJ, Brooks PM. Clinical pharmacokinetics of the salicylates. Clin Pharmacokinet. 1985;10(2):164–77. https://doi.org/10.2165/00003088-198510020-00004.CrossRefPubMed

Kowalski ML, Stevenson DD. Classification of reactions to nonsteroidal antiinflammatory drugs. Immunol Allergy Clin North Am. 2013;33(2):135–45. https://doi.org/10.1016/j.iac.2012.10.008 (Epub 2012 Nov 27).CrossRefPubMed

Laidlaw TM, Cahill KN. Current knowledge and management of hypersensitivity to aspirin and NSAIDs. J Allergy Clin Immunol Pract. 2017;5(3):537–45. https://doi.org/10.1016/j.jaip.2016.10.021.CrossRefPubMed

Tantry US, Gurbel PA. Rapid desensitization of the patients with aspirin hypersensitivity and coronary artery disease. Circ Cardiovasc Interv. 2017;10(2): e004881. https://doi.org/10.1161/CIRCINTERVENTIONS.117.004881.CrossRefPubMed

10.

Cook KA, White AA. Rapid aspirin challenge in patients with aspirin allergy and acute coronary syndromes. Curr Allergy Asthma Rep. 2016;16(2):11. https://doi.org/10.1007/s11882-015-0593-2.CrossRefPubMed

11.

Sanchez-Borges M, Capriles-Hulett A. Atopy is a risk factor for non-steroidal anti- inflammatory drug sensitivity. Ann Allergy Asthma Immunol. 2000;84:101–6.CrossRef

12.

Sanchez-Borges M, Capriles-Hulett A, Caballero-Fonseca F. Cutaneous reactions to aspirin and nonsteroidal anti-inflammatory drugs. Clin Rev Allergy Immunol. 2003;24:125–35.CrossRef

13.

Aimo A, De Caterina R. Aspirin for primary prevention of cardiovascular disease: advice for a decisional strategy based on risk stratification. Anatol J Cardiol. 2020;23(2):70–8. https://doi.org/10.14744/AnatolJCardiol.2019.89916.CrossRefPubMed

14.

Arnett DK, Blumenthal RS, Albert MA, Buroker AB, Goldberger ZD, Hahn EJ, Himmelfarb CD, Khera A, Lloyd-Jones D, McEvoy JW, Michos ED, Miedema MD, Muñoz D, Smith SC Jr, Virani SS, Williams KA Sr, Yeboah J, Ziaeian B. 2019 ACC/AHA guideline on the primary prevention of cardiovascular disease: executive summary: a report of the American College of Cardiology/American Heart Association Task Force on clinical practice guidelines. J Am Coll Cardiol. 2019;74(10):1376–414. https://doi.org/10.1016/j.jacc.2019.03.009 (Epub 2019 Mar 17; Erratum in: J Am Coll Cardiol. 2019 Sep 10;74(10):1428-1429. Erratum in: J Am Coll Cardiol. 2020 Feb 25;75(7):840).CrossRefPubMedPubMedCentral

15.

Sangkuhl K, Shuldiner AR, Klein TE, Altman RB. Platelet aggregation pathway. Pharmacogenet Genomics. 2011;21(8):516–521. https://doi.org/10.1097/fpc.0b013e3283406323

16.

Patrono C. Antiplatelet strategies. Eur Heart J Suppl. 2002;4(suppl_A):A42–7.CrossRef

17.

Çamli E, Verdiyev H, Babayiğit E, Kurt E, Ulus T. How to manage aspirin hypersensitivity in a patient with ST-segment elevation myocardial infarction and a drug-eluting stent. Turk Kardiyol Dern Ars. 2021;49(2):167–70. https://doi.org/10.5543/tkda.2021.67827.CrossRefPubMed

18.

Barillà F, Pulcinelli FM, Mangieri E, Torromeo C, Tanzilli G, Dominici T, Pellicano M, Paravati V, Acconcia MC, Gaudio C. Clopidogrel plus indobufen in acute coronary syndrome patients with hypersensitivity to aspirin undergoing percutaneous coronary intervention. Platelets. 2013;24(3):183–8. https://doi.org/10.3109/09537104.2012.686072 (Epub 2012 May 30).CrossRefPubMed

19.

Trelle S, Reichenbach S, Wandel S, Hildebrand P, Tschannen B, Villiger PM, Egger M, Jüni P. Cardiovascular safety of non-steroidal anti-inflammatory drugs: network meta-analysis. BMJ. 2011;11(342): c7086. https://doi.org/10.1136/bmj.c7086.CrossRef

20.

Allahham M, Lerman A, Atar D, Birnbaum Y. Why not dipyridamole: a review of current guidelines and re-evaluation of utility in the modern era. Cardiovasc Drugs Ther. 2021. https://doi.org/10.1007/s10557-021-07224-9 (Epub ahead of print).CrossRefPubMedPubMedCentral

21.

Liang EH, Kim CY, Sheikh J, Samant SA. Higher-starting-dose protocols in patients with coronary artery disease and aspirin hypersensitivity. Ann Allergy Asthma Immunol. 2019;123(5):512–5. https://doi.org/10.1016/j.anai.2019.08.013 (Epub 2019 Aug 22).CrossRefPubMed

22.

Marwa K, Kondamudi NP. Type IV hypersensitivity reaction. [Updated 2021 Aug 14]. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2021. Available from: https://www.ncbi.nlm.nih.gov/books/NBK562228/

23.

Abbas M, Moussa M, Akel H. Type I Hypersensitivity reaction. [Updated 2021 Jul 21]. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2021. Available from: https://www.ncbi.nlm.nih.gov/books/NBK560561/

24.

Rossini R, Angiolillo DJ, Musumeci G, et al. Aspirin desensitization in patients undergoing percutaneous coronary interventions with stent implantation. Am J Cardiol. 2008;101(6):786–9.CrossRef

25.

Verdoia M, Barbieri L, Schaffer A, Nardin M, Suryapranata H, De Luca G. Acetylsalicylic acid desensitization in patients with coronary artery disease: a comprehensive overview of currently available protocols. Vascul Pharmacol. 2016;80:43–9. https://doi.org/10.1016/j.vph.2015.09.005 (Epub 2015 Oct 9).CrossRefPubMed

26.

Feng CH, White AA, Stevenson DD. Characterization of aspirin allergies in patients with coronary artery disease. Ann Allergy Asthma Immunol. 2013;110(2):92–5. https://doi.org/10.1016/j.anai.2012.11.013.CrossRefPubMed

27.

Pattanaik D, Lieberman P, Das P. Aspirin sensitivity and coronary artery disease: implications for the practicing cardiologist. Future Cardiol. 2012;8(4):555–62. https://doi.org/10.2217/fca.12.38.CrossRefPubMed

28.

Stevenson DD, Simon RA. Selection of patients for aspirin desensitization treatment. J Allergy Clin Immunol. 2006;118(4):801–4.CrossRef

29.

Wong JT, Nagy CS, Krinzman SJ, Maclean JA, Bloch KJ. Rapid oral challenge-desensitization for patients with aspirin-related urticaria-angioedema. J Allergy Clin Immunol. 2000;105(5):997–1001.CrossRef

30.

Silberman S, Neukirch-Stoop C, Steg PG. Rapid desensitization procedure for patients with aspirin hypersensitivity undergoing coronary stenting. Am J Cardiol. 2005;95(4):509–10.CrossRef

31.

Gollapudi RR, Teirstein PS, Stevenson DD, Simon RA. Aspirin sensitivity: implications for patients with coronary artery disease. JAMA. 2004;292(24):3017–23. https://doi.org/10.1001/jama.292.24.3017.CrossRefPubMed

32.

McMullan KL. Aspirin allergy in patients with myocardial infarction: the allergist’s role. Ann Allergy Asthma Immunol. 2014;112(2):90–3. https://doi.org/10.1016/j.anai.2013.11.020 (Epub 2013 Dec 17).CrossRefPubMed

33.

Lambrakis P, Rushworth GF, Adamson J, Leslie SJ. Aspirin hypersensitivity and desensitization protocols: implications for cardiac patients. Ther Adv Drug Saf. 2011;2(6):263–70. https://doi.org/10.1177/2042098611422558.CrossRefPubMedPubMedCentral

34.

Hajar R. Risk factors for coronary artery disease: historical perspectives. Heart Views. 2017;18(3):109–14. https://doi.org/10.4103/HEARTVIEWS.HEARTVIEWS_106_17.CrossRefPubMedPubMedCentral

Title: Coronary Artery Disease and Aspirin Intolerance: Background and Insights on Current Management
Authors: Ravi A. Thakker
Leonardo Salazar
Deaa Abu Jazar
Pooja Bhakta
Bryan Baker
Chandani Patel
Ayman Elbadawi
Mayank Agarwal
Aiham Albaeni
Mohammed Saleh
Jonathan Esclovan
Danielle El Haddad
Hashim Alwash
Ankur Kalra
Sachin S. Goel
Robert Jay Widmer
Khaled Chatila
Wissam Khalife
Afaq Motiwala
Jennifer McCracken
Hani Jneid
Syed Gilani
Publication date: 28-03-2022
Publisher: Springer Healthcare
Keywords: Acute Coronary Syndrome
Angioedema
Arterial Diseases
Urticaria
Published in: Cardiology and Therapy / Issue 2/2022
Print ISSN: 2193-8261
Electronic ISSN: 2193-6544
DOI: https://doi.org/10.1007/s40119-022-00255-9

Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Pediatric Cardiology Video

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

Cardiopulmonary Comorbidity Video

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Valvular Heart Disease Video

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discuss last year's major advances in heart failure and cardiomyopathies.

ACC 2024 Congress Coverage

Heart Failure Video

Year in Review: Heart failure and cardiomyopathies

Watch now

Watch this official video from ACC.24. Dr. Biykem Bozkurt discuss last year's major advances in heart failure and cardiomyopathies.

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

16-04-2024 Type 2 Diabetes News

Incentivised to exercise

11-04-2024 Lifestyle Modifications News

New intervention for STEMI-related cardiogenic shock

10-04-2024 Myocardial Infarction News

» View more highlights on the ACC 2024 congress hub page

Image Credits

STEP AAG HeroTeaserCollection image/© Tarek / Generated with AI / Stock.adobe.com, ACC 2024 Pediatric and Congenital Heart Disease: Year in Review/© 2024 American College of Cardiology, ACC 2024 Pulmonary Vascular Disease: Year in Review/© 2024 American College of Cardiology, ACC 2024 Valvular Heart Disease: Year in Review/© 2024 American College of Cardiology, ACC 2024 HF and Cardiomyopathies: Year in Review/© 2024 American College of Cardiology, Woman out walking/© Seventyfour / stock.adobe.com (symbolic image with model), Woman checking smartwatch /© saltdium / stock.adobe.com (symbolic image with model), Cardiac catheterization/© Damian / stock.adobe.com

At a glance: The STEP trials

Springer Medicine

Abstract

Please log in to get access to this content

Other articles of this Issue 2/2022

Populational Perceptions Regarding Decision to Visit the Emergency Room with Chest Pain During COVID-19

Left Ventricular Hypertrophy: Etiology-Based Therapeutic Options

Patients with Atrial Fibrillation Benefit from SAVR with Surgical Ablation Compared to TAVR Alone

Evaluation of Intima-Media Thickness and Arterial Stiffness as Early Ultrasound Biomarkers of Carotid Artery Atherosclerosis

Treatment Changes, Healthcare Resource Utilization, and Costs Among Patients with Symptomatic Obstructive Hypertrophic Cardiomyopathy: A Claims Database Study

Endovascular Repair of an Iliac Arteriovenous Fistula in a 30-Year-Old Female Patient with Suspected Severe Cardiac Insufficiency: A Case Report

Highlights from the ACC 2024 Congress

ACC 2024 Congress Coverage